A Phase I Study of BIIB015, a Humanized, IgG1 [immunoglobulin G 1], DM4-Conjugated, Anti-Cripto, Monoclonal Antibody, for the Treatment of Subjects With Relapsed or Refractory Solid Tumors

Trial Profile

A Phase I Study of BIIB015, a Humanized, IgG1 [immunoglobulin G 1], DM4-Conjugated, Anti-Cripto, Monoclonal Antibody, for the Treatment of Subjects With Relapsed or Refractory Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Jun 2015

At a glance

  • Drugs BIIB 015 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Biogen
  • Most Recent Events

    • 25 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Aug 2011 Actual end date (Jun 2011) added as reported by ClinicalTrials.gov.
    • 12 May 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top